MarketMoodz
Gilead, Merck Halt Trodelvy–Keytruda Lung Trial; Market Impact
Gilead Sciences and Merck announced the discontinuation of the Phase 3 KEYNOTE‑D46/EVOKE‑03 trial testing Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) in previously untreated metastatic non‑small cell lung cancer with high PD‑L1 after a Data Monitoring Committee review. The report — sourced to a secondary account and pending company confirmation and full data disclosure — raises immediate questions about the commercial upside for that combination and the valuation of oncology assets in both companies’ pipelines.
Key Takeaways
- Gilead and Merck reportedly stopped the Phase 3 Trodelvy+Keytruda trial after a DMC review citing progression‑free survival that did not reach statistical significance and a low probability of achieving a meaningful overall survival benefit.
- The combination showed a numerical PFS improvement but failed to meet statistical significance; investigators said the chance of a positive OS at final analysis was low.
- No new safety signals were reported in the note; companies plan to present full data at a future medical meeting.
- Separately, the firms reportedly posted positive Phase 3 results for an investigational once‑weekly oral HIV regimen (islatravir + lenacapavir) in ISLEND‑1/ISLEND‑2 with planned regulatory filings mentioned.
- Reported market moves were mixed: Gilead shares cited down ~2.3% to $125.18 while Merck was cited up ~0.5% to $120.07, though these figures are time‑sensitive and unconfirmed.
People Involved
- No specific individuals mentioned
Entities Involved
- Gilead Sciences Inc. (GILD)Sponsor/developer of Trodelvy and co‑partner in the KEYNOTE‑D46/EVOKE‑03 trial
- Merck & Co., Inc. (MRK)Sponsor/developer of Keytruda and co‑partner in the KEYNOTE‑D46/EVOKE‑03 trial
- Trodelvy (sacituzumab govitecan)Antibody‑drug conjugate evaluated in combination with Keytruda
- Keytruda (pembrolizumab)Merck PD‑1 inhibitor evaluated in combination with Trodelvy
- Islatravir + Lenacapavir (ISLEND‑1/ISLEND‑2)Investigational once‑weekly oral HIV regimen reported to have positive Phase 3 results
- KEYNOTE‑D46/EVOKE‑03Phase 3 trial in previously untreated metastatic NSCLC with high PD‑L1
- BenzingaSecondary news source reporting the trial discontinuation
MarketMoodz Analysis
For investors, a stopped Phase 3 trial driven by an unfavorable DMC review is a near‑term negative for the oncology narrative behind both Gilead and Merck because Phase 3 readthroughs set expectations for commercial scale and peak sales. Combination immuno‑oncology (IO) strategies carry high R&D and marketing costs; failure to show a statistically significant PFS or a credible path to overall survival reduces the likelihood of premium pricing and compresses the risk/return for related assets. That matters for valuation models that had assumed the Trodelvy+Keytruda combo would meaningfully extend market share in frontline PD‑L1 high non‑small cell lung cancer.
The headline is tempered by a counterbalancing data point: the reported positive Phase 3 readout for the investigational once‑weekly islatravir + lenacapavir HIV regimen, which—if confirmed and advanced into regulatory filings—would diversify near‑term commercial prospects for both companies and partially offset oncology setbacks. Historically, ADC plus PD‑1 combinations have produced mixed results, and stopping for low probability of OS benefit is a common DMC action to avoid exposing patients to ineffective regimens. Investors should watch for company press releases and the medical‑meeting presentation of full data, which will clarify effect sizes, subgroup signals, and safety details that determine whether any residual value remains in the combination.
Near term, monitor official confirmations from Gilead and Merck, upcoming analyst updates, and regulatory filing plans for the HIV program; any clearer guidance on milestone write‑downs, pipeline reprioritization, or M&A commentary around Keytruda patent dynamics could drive further re‑rating. For portfolio managers, this episode reinforces the need to size exposures to binary Phase 3 readouts and to stress‑test models for combinations where overall survival is the decisive endpoint.
Source: Original Article